Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein

Audrey Courcoul; Emmanuelle Vignot; Roland Chapurlat

doi:10.1016/j.jbspin.2013.06.013

Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein

Joint Bone Spine. 2014 Mar;81(2):175-7. doi: 10.1016/j.jbspin.2013.06.013. Epub 2013 Aug 13.

Authors

Audrey Courcoul¹, Emmanuelle Vignot¹, Roland Chapurlat²

Affiliations

¹ Inserm UMR1033, université de Lyon, Hospices Civils de Lyon, Department of rheumatology, Pavillon F, hospital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
² Inserm UMR1033, université de Lyon, Hospices Civils de Lyon, Department of rheumatology, Pavillon F, hospital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. Electronic address: roland.chapurlat@chu-lyon.fr.

PMID: 23953221
DOI: 10.1016/j.jbspin.2013.06.013

Abstract

Erdheim-Chester disease is a rare non-langerhans systemic histiocytosis of unknown origin, associated with bone diseases and severe visceral complications. Therapies have been disappointing. A recombinant form of interleukin-1 receptor antagonist (anakinra) has been used in a few cases when usual treatment fails. We report a new case of successfully interleukin-1 receptor antagonist treatment in Erdheim-Chester disease.

Keywords: Anakinra; Erdheim-Chester disease; Histiocytosis; Interleukin-1 receptor antagonist protein.

Publication types

Case Reports

MeSH terms

Antirheumatic Agents / therapeutic use*
Erdheim-Chester Disease / drug therapy*
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Male
Middle Aged

Substances

Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein